117 related articles for article (PubMed ID: 7434385)
1. [Clinical experience with daily doses of misonidazole (author's transl)].
Kogelnik HD; Reinartz G; Szepesi T; Seitz W; Wurst F; Mamoli B; Wessely P; Stark H
Strahlentherapie; 1980 Nov; 156(11):758-64. PubMed ID: 7434385
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with misonidazole: high dose fractions versus daily low doses.
Kogelnik HD
Cancer Clin Trials; 1980; 3(2):179-86. PubMed ID: 6253098
[TBL] [Abstract][Full Text] [Related]
3. [Clinical experiences with the radiation-sensitizing agent misonidazole].
Kogelnik HD; Szepesi T; Kärcher KH; Seitz W
Strahlentherapie Sonderb; 1978; 75():115-9. PubMed ID: 162327
[No Abstract] [Full Text] [Related]
4. Plasma concentrations of misonidazole.
Notter G; Rylander U; Turesson I
Strahlentherapie; 1980; 156(10):714-8. PubMed ID: 7434379
[TBL] [Abstract][Full Text] [Related]
5. I.V. misonidazole (NSC 261037). Report of initial clinical experience.
Schwade JG; Strong JM; Gangji D
Cancer Clin Trials; 1981; 4(1):33-9. PubMed ID: 7214660
[No Abstract] [Full Text] [Related]
6. Misonidazole peripheral neuropathy: its relationship to plasma concentration and other drugs.
Walker MD; Strike TA
Cancer Clin Trials; 1980; 3(2):105-9. PubMed ID: 6253094
[TBL] [Abstract][Full Text] [Related]
7. [Clinical evaluation of hypoxic cell sensitizer (Misonidazole)].
Asakawa H; Watarai J; Hoshino T
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1225-30. PubMed ID: 6732250
[TBL] [Abstract][Full Text] [Related]
8. [Clinical testing of the radiosensitizer RO-07-0582 (misonidazole). Dose tolerance, toxicity and pharmacokinetic studies, preliminary report (author's transl)].
Bataini JP; Bernier J; de Narbonne J; Brugère J; Jaulerry C; Brunin F
Bull Cancer; 1978; 65(4):482-5. PubMed ID: 371710
[No Abstract] [Full Text] [Related]
9. [Clinical experiences with the radiosensitizer Misonidazol (author's transl)].
Bamberg M; Tamulevicius P; Streffer C; Scherer E
Strahlentherapie; 1981 Aug; 157(8):524-36. PubMed ID: 7268822
[No Abstract] [Full Text] [Related]
10. Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.
Kogelnik HD; Meyer JH; Jentzsch K; Szepesi T; Kärcher KH; Maida E; Mamoli B; Wessely P; Zaunbauer F
Br J Cancer Suppl; 1978 Jun; 3():281-5. PubMed ID: 209810
[TBL] [Abstract][Full Text] [Related]
11. [Clinical trials of hypoxic cell sensitizer misonidazole].
Onoyama Y
Gan No Rinsho; 1983 May; 29(6):718-25. PubMed ID: 6348345
[TBL] [Abstract][Full Text] [Related]
12. Peripheral neuropathy related to misonidazole: incidence and pathology.
Urtasun RC; Chapman JD; Feldstein ML; Band RP; Rabin HR; Wilson AF; Marynowski B; Starreveld E; Shnitka T
Br J Cancer Suppl; 1978 Jun; 3():271-5. PubMed ID: 209809
[TBL] [Abstract][Full Text] [Related]
13. The role of microsomal enzyme inducers in the reduction of misonidazole neurotoxicity.
Jones DH; Bleehen NM; Workman P; Smith NC
Br J Radiol; 1983 Nov; 56(671):865-70. PubMed ID: 6626878
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials of misonidazole in the United States.
Wasserman TH; Stetz J; Phillips TL
Cancer Clin Trials; 1981; 4(1):7-16. PubMed ID: 7214664
[TBL] [Abstract][Full Text] [Related]
15. Misonidazole in the preoperative and radical radiotherapy of bladder cancer.
Awwad HK; El Merzabani MM; El Badawy S; Ezzat S; Akoush H; Abd El Moneim H; Saiid A; Soliman O; Khafagy M; Burgers MV
Cancer Clin Trials; 1980; 3(3):275-80. PubMed ID: 7438324
[TBL] [Abstract][Full Text] [Related]
16. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.
Saunders ME; Dische S; Anderson P; Flockhart IR
Br J Cancer Suppl; 1978 Jun; 3():268-70. PubMed ID: 209808
[TBL] [Abstract][Full Text] [Related]
17. Multiple daily fractionation (MDF) radiotherapy in association with hyperthermia and/or misonidazole: experimental and clinical results.
Arcangeli G; Barocas A; Mauro F; Nervi C; Spanò M; Tabocchini A
Cancer; 1980 Jun; 45(11):2707-11. PubMed ID: 7379004
[TBL] [Abstract][Full Text] [Related]
18. Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037).
Phillips TL; Wasserman TH; Johnson RJ; Levin VA; VanRaalte G
Cancer; 1981 Oct; 48(8):1697-704. PubMed ID: 6269723
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of radiotherapy with misonidazole in head and neck cancer.
Paterson IC; Dawes PJ; Henk JM; Moore JL
Clin Radiol; 1981 Mar; 32(2):225-9. PubMed ID: 7214840
[TBL] [Abstract][Full Text] [Related]
20. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
Dische S; Saunders MI; Flockhart IR
Br J Cancer Suppl; 1978 Jun; 3():318-21. PubMed ID: 209811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
